Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
CAMBRIDGE, Mass., March 28, 2017 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 16th Annual Needham Healthcare Conference in New York, NY on Wednesday, April 5, 2017 at 12:10pm Eastern Time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: http://investors.vcel.com/events.cfm.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
